# K36 Therapeutics, Inc.

> K36 Therapeutics is a Cambridge, Massachusetts clinical-stage biotech developing first-in-class oral small-molecule inhibitors of NSD2/MMSET, an epigenetic enzyme that drives hard-to-treat cancers. Its lead candidate, gintemetostat (KTX-1001), is in Phase 1 for relapsed/refractory multiple myeloma carrying the t(4;14) translocation, and a second program, KTX-2001, targets metastatic castration-resistant prostate cancer. Backed by Atlas Venture, F-Prime Capital, Eight Roads Ventures, Nextech Invest and Bristol Myers Squibb, K36 has raised roughly $100M+ to translate chromatin biology into precision cancer medicines.

- **Founded:** 2021
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Terrence Connolly (President & Chief Executive Officer)
- **Team size:** ~13 employees
- **Products:** Gintemetostat (KTX-1001), KTX-2001
- **Notable:** Advanced the first-ever NSD2 inhibitor (gintemetostat) into human clinical trials., Reported first-in-human data showing target engagement (H3K36me2 suppression) and early clinical activity in heavily pretreated multiple myeloma at ASH 2025., Raised approximately $100M+ across Series A and B financings from top-tier life-science investors.

## Products & services

- **Gintemetostat (KTX-1001)** — First-in-class, oral, selective small-molecule inhibitor of the histone methyltransferase NSD2/MMSET. In a Phase 1 trial (K36-MMSET-001) for relapsed/refractory multiple myeloma patients with the t(4;14) translocation, designed to reduce H3K36me2, restore normal gene expression, and re-sensitize tumor cells to therapy. Tested as monotherapy and in combination with carfilzomib, mezigdomide, or pomalidomide.
- **KTX-2001** — Oral, selective NSD2 inhibitor in a Phase 1 trial (STRIKE-001, NCT07103018) for metastatic castration-resistant prostate cancer (mCRPC), evaluated as monotherapy and in combination with the androgen receptor inhibitor darolutamide.

## Achievements

- Advanced the first-ever NSD2 inhibitor (gintemetostat) into human clinical trials.
- Reported first-in-human data showing target engagement (H3K36me2 suppression) and early clinical activity in heavily pretreated multiple myeloma at ASH 2025.
- Raised approximately $100M+ across Series A and B financings from top-tier life-science investors.
- Expanded the NSD2 franchise into a second indication (prostate cancer) with KTX-2001.

## Latest updates

- **2026-01** — Highlighted first-in-human KTX-2001 prostate cancer study design at the ASCO Genitourinary Cancers Symposium 2026.
- **2025-12** — Completed dosing of the first cohort in the Phase 1 STRIKE-001 trial of KTX-2001 in prostate cancer and announced a new Chief Medical Officer.
- **2025-12** — Presented first-in-human clinical data for gintemetostat (KTX-1001) at ASH 2025 and appointed Dr. Shinta Cheng, M.D., Ph.D., as Chief Medical Officer.
- **2025-09** — Presented new preclinical data supporting the ongoing Phase 1 trial of KTX-1001 at the 22nd Annual International Myeloma Society meeting.
- **2025-09** — Provided a clinical update on KTX-1001 in multiple myeloma and began dosing high-risk patients with combination regimens.

## Links

- Website: https://k36tx.com
- LinkedIn: https://www.linkedin.com/company/k36-therapeutics
- Twitter/X: https://twitter.com/k36tx
- Facebook: https://facebook.com/k36tx/

---

Profile page: https://yespress.io/k36-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-20